Spinal Cord Injury - Healing Genes

Spinal Cord Injury

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Adipose Stem Cells for Traumatic Spinal Cord Injury (CELLTOP)

Phase I Clinical Trial of Autologous Adipose Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury

Phase 1


Doctors at the Mayo Clinic in MN are recruiting patients with spinal cord injuries to trial an investigatory treatment using adipose (fat)-derived mesenchymal stem cells (AD-MSCs). The researchers hope these regenerative cells may improve sensory and motor function. They will be drawn via liposuction procedure, processed in a lab, then delivered intrathecally (into the spine). Patients will then be evaluated at day 2, day 3, week 1, week 2, week 4, week 24, weeks 48, week 72 and week 96.


  • Be 18 years of age and older
  • Have a spinal cord injury (SCI) which must be traumatic, blunt/non-penetrating in nature and not degenerative
  • Females of childbearing potential must have a negative pregnancy test prior to receiving the study drug and will agree to use adequate contraception (hormonal/barrier method or abstinence) from the time of screening to a period of 1 year following completion of the drug treatment cycle.


  1. Prescreening at the study site to confirm eligibility of the patient to participate.
  2. Adipose tissue is obtained from the patient and processed in a lab.
  3. The stem cells are injected intrathecally (into the spine).
  4. Patients will then be evaluated at day 2, day 3, week 1, week 2, week 4, week 24, weeks 48, week 72 and week 96.


Trials will take place at the Mayo Clinic in Rochester in Rochester, MN, Map.


Bambi L Wessel  |  (507) 293-1963  |  [email protected]

Sandy Goncalves, MS  |  (507) 538-6546  |  [email protected]



Allan Dietz


Or go online:



Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader